Evoke Pharma, Inc. (NASDAQ:EVOK) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday.

According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “

Several other brokerages have also recently issued reports on EVOK. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a research report on Tuesday, August 15th. Seaport Global Securities reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research report on Friday, October 6th. Finally, ValuEngine cut Evoke Pharma from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $8.50.

Shares of Evoke Pharma (NASDAQ EVOK) traded down 3.87% during trading on Thursday, hitting $3.73. 238,775 shares of the company were exchanged. Evoke Pharma has a 1-year low of $1.35 and a 1-year high of $4.55. The stock’s market capitalization is $57.40 million. The company has a 50 day moving average of $3.17 and a 200-day moving average of $2.75.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.15). During the same period in the prior year, the company posted ($0.41) earnings per share. On average, analysts forecast that Evoke Pharma will post ($0.87) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/12/evoke-pharma-inc-evok-lifted-to-hold-at-zacks-investment-research.html.

An institutional investor recently raised its position in Evoke Pharma stock. Vanguard Group Inc. boosted its holdings in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 15.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 523,650 shares of the specialty pharmaceutical company’s stock after purchasing an additional 68,544 shares during the quarter. Vanguard Group Inc. owned about 3.40% of Evoke Pharma worth $1,341,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.88% of the company’s stock.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.